Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,581.82
(
1.16%
)
US TECH 100
23,544.40
(
1.13%
)
Dow Jones
46,210.85
(
1.39%
)
Brent Oil
99.54
(
-7.95%
)
Bitcoin
70,375.08
(
3.74%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 130335

Saturday, 11/05/2011 1:43:16 PM

Saturday, November 05, 2011 1:43:16 PM

Post# of 257269

[DEB025] could find a market after years of nuke/riba or nuke monotherapy but I would expect this to be very limited.

Why would DEB025 have to be relegated to the second- or third-line setting? If it can add modest efficacy to a nuke-based regimen with no increase in resistance, I see no reason why DEB025 is unsuited to the first-line setting.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today